Various medications that treat narcolepsy are available, and treatment plans can vary based on individual ... their side effects often make them less ideal for regular use. Prozac (fluoxetine) is a ...

Various medications that treat narcolepsy are available ... their side effects often make them less ideal for regular use.

The narcolepsy treatment market is projected to grow from USD 5,301.6 million in 2024 to USD 8,718.3 million by 2034, at a ...

However, an individual’s risk with the use of any drug may still result in unacceptable consequences. Using the categories outlined above, medications for the treatment of the most common sleep ...

Avadel Pharmaceuticals expects its narcolepsy treatment Lumryz to drive strong revenue growth in the fourth quarter and into 2025, preliminary earnings show.

People who live with narcolepsy — about one out of every ... and then became known as GHB and criminally used as a date rape drug — has been sold under the brand name Xyrem after gaining ...

Central nervous system (CNS) specialist Neuraxpharm Group has acquired Provigil (modafinil) and Nuvigil (armodafinil), both of which are indicated for the treatment of excessive daytime sleepiness ...

The FDA has also extended approval for LUMRYZ's use to pediatric narcolepsy ... A leading sleep expert highlighted the drug's transformative potential across narcolepsy subtypes and idiopathic ...

The FDA has expanded the approval of Lumryz (sodium oxybate) extended-release oral suspension to include treatment of pediatric narcolepsy.

Sales of its narcolepsy drug, LUMRYZ rose by 150% YoY. AVDL expects net product revenue for 2025 in the range of $240 million to $260 million. Get Real-Time News and Alerts for Your Portfolio ...

The world’s largest genetic study into depression has uncovered life-changing discoveries that will revolutionise treatments ...